Ranbaxy acquires Bangalore vaccine firm Biovel

Biovel’s development pipeline comprises of vaccines and biotherapeutics, the two companies said in a statement.

“This transaction with Biovel provides us an entry platform to manufacture vaccines as well as biotherapeutics. The vaccine and biotherapeutics business will be an important part of our growth strategy," Ranbaxy chief executive Atul Sobti said in the statement.

Ranbaxy is majority owned by Japan’s Daiichi Sankyo.

Milestone Alert!
Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!